科创新公司扩大其PNKP抑制剂候选药物ONC010的关键中间产品. Onco-Innovations scales up key intermediates for its PNKP inhibitor drug candidate ONC010.

科创新公司宣布成功扩大用于生产其候选PNKP抑制剂药物ONC010的活性制药成分的主要中间体. Onco-Innovations announced the successful scale-up of key intermediates used in producing the active pharmaceutical ingredient for its PNKP inhibitor drug candidate ONC010. 通过与达尔顿制药服务公司合作,从实验室到中等规模的进步证明了工艺稳定性和可扩展性. Conducted in collaboration with Dalton Pharma Services, the advancement from laboratory to intermediate scale demonstrates process robustness and scalability. 这一里程碑加强了公司的制造基础,支持临床前研究,配方开发和IND启用活动,因为该公司旨在将基于纳米粒子的治疗转向首次人类临床试验. This milestone strengthens the company's manufacturing foundation, supporting preclinical studies, formulation development, and IND-enabling activities as the firm aims to move the nanoparticle-based therapy toward first-in-human clinical trials.